Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of PT217 combined with chemotherapy and/or a PD-L1 inhibitor in DLL3-expressing neuroendocrine carcinoma
CTR20252759Phase 2Active
- Sponsor
- F-star
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of peluntamig in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by F-star. Started Jul 2025; status: active.
02
Drugs
peluntamig
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on CTR20252759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252759.